What is the ideal treatment timing for bisphosphonate therapy? | MDedge

Article Type

Changed

Mon, 01/04/2021 - 15:53

Display Headline

What is the ideal treatment timing for bisphosphonate therapy?

Author(s)

John T. Repke, MD

Citation: Drieling RL, LaCroix AZ, Beresford SA, et al. Long-term oral bisphosphonate therapy and fractures in older women: the Women’s Health Initiative. J Am Geriatr Soc. 2017;65(9):1924-1931.

Author and Disclosure Information

Dr. Repke is Professor, Department of Obstetrics and Gynecology, Penn State University College of Medicine, Hershey, Pennsylvania.

The author reports no financial relationships relevant to this video.

Issue

OBG Management - 29(11)

Publications

Sections

Expert Commentary

Author(s)

John T. Repke, MD

Author(s)

John T. Repke, MD

Author and Disclosure Information

Dr. Repke is Professor, Department of Obstetrics and Gynecology, Penn State University College of Medicine, Hershey, Pennsylvania.

The author reports no financial relationships relevant to this video.

Author and Disclosure Information

Dr. Repke is Professor, Department of Obstetrics and Gynecology, Penn State University College of Medicine, Hershey, Pennsylvania.

The author reports no financial relationships relevant to this video.

Citation: Drieling RL, LaCroix AZ, Beresford SA, et al. Long-term oral bisphosphonate therapy and fractures in older women: the Women’s Health Initiative. J Am Geriatr Soc. 2017;65(9):1924-1931.

Citation: Drieling RL, LaCroix AZ, Beresford SA, et al. Long-term oral bisphosphonate therapy and fractures in older women: the Women’s Health Initiative. J Am Geriatr Soc. 2017;65(9):1924-1931.

Issue

OBG Management - 29(11)

Issue

OBG Management - 29(11)

Publications

Publications

Article Type

Display Headline

What is the ideal treatment timing for bisphosphonate therapy?

Display Headline

What is the ideal treatment timing for bisphosphonate therapy?

Sections

Expert Commentary

Inside the Article

WHAT DOES THIS MEAN FOR PRACTICE?

Oral bisphosphonates remain in our armamentarium for reducing fracture in postmenopausal patients
Ideal duration of therapy remains unclear
Counsel patients: up to 2 y of therapy reduces fracture risk; >10 y of therapy may increase fracture risk

Disallow All Ads

Content Gating

No Gating (article Unlocked/Free)

Alternative CME

Disqus Comments

Default

Consolidated Pubs: Do Not Show Source Publication Logo

Use ProPublica

Conference Recap Checkbox

Not Conference Recap

Clinical Edge

Display the Slideshow in this Article

Medscape Article

Teaser Media